by Instem Team | Mar 3, 2026 | Resources
Organizations today must deliver consistent, high‑quality products and services amid rising customer expectations and increasing regulatory demands. Traditional, reactive inspection methods are no longer enough—modern quality assurance (QA) requires proactive systems...
by Instem Team | Mar 2, 2026 | Clinical, Resources
The biostatistics industry is moving towards a language-agnostic modality. SAS has been the go-to programming language for biostatistics for decades. But R and other open-source languages are increasingly being used for their distinct capabilities and methodologies,...
by Instem Team | Feb 23, 2026 | In Silico & Data Insights, Leadscope, Regulatory Submission
My Thoughts on NAMs and the Future of Drug Development: Progress Demands Leadership Donna Robinson, Chief Commercial Officer, Instem New ideas, methods, and technologies appear all the time, especially in the biomedical space. While the hype is often well-earned, many...
by Instem Team | Feb 20, 2026 | Resources
Preclinical research teams face growing pressure to deliver complete, traceable, and inspection‑ready data across both GLP studies and day‑to‑day colony operations. Yet many organizations still manage these domains separately, using solutions like Provantis® for...
by Instem Team | Jan 28, 2026 | Clinical, Company News, Press Releases
We are excited to announce the revival of the d-wise brand to represent Instem’s Clinical Trial Analytics and Transparency offerings. This movement returns our clinical portfolio to its roots while reinforcing our dedication to supporting and enriching the clinical...
